Search
Invasive pneumococcal disease remains a major cause of hospitalization and death in Papua New Guinean (PNG) children. We assessed mucosal IgA and IgG responses in PNG infants vaccinated with pneumococcal conjugate vaccine (PCV) followed by a pneumococcal polysaccharide vaccine (PPV) booster.
Researchers developing a nasal therapy to prevent childhood ear infections and reduce overuse of antibiotics have received $300,000 in top-up funding.
The aim of this review was to investigate the impact of short message service (SMS)-based interventions on childhood and adolescent vaccine coverage and timeliness.
HIV postexposure prophylaxis (PEP) following child sexual assault (CSA) is recommended in select cases. High rates of poor adherence to PEP are reported. We evaluated adherence to the recommended management of children following CSA at the tertiary pediatric facility in Western Australia and compared our approach with international guidelines.
The Platform trial In COVID-19 priming and BOOsting (PICOBOO) is a multi-site, adaptive platform trial designed to generate evidence of the immunogenicity, reactogenicity, and cross-protection of different booster vaccination strategies against severe acute respiratory syndrome coronavirus 2 and its variants, specific for the Australian context.
A first-of-its-kind national study looking at the optimal COVID-19 vaccination strategies for children and adolescents is set to begin at Perth’s The Kids Research Institute Australia thanks to a $3.8 million funding injection from the Australian Government’s Medical Research Future Fund (MRFF).
Researchers using powerful microscopes have identified bacterial slime in the lungs of some children with persistent wet coughs.
Tiny babies could soon have much-needed protection from community transmission of potentially deadly whooping cough thanks to a world-first nasal spray vaccine being trialed at The Kids Research Institute Australia.
The Kids Research Institute Australia researchers have found close to 40 per cent of Aboriginal babies begin to develop middle ear infections between two and four months of age in a first of its kind study in metropolitan Perth.
Paediatric infectious disease expert and clinician-scientist Associate Professor Asha Bowen has been named as the Emerging Leader in Science at the country’s most prestigious science awards – the Australian Museum Eureka Prizes.